ß2-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.

Babette M. Pluim*, Olivier de Hon, J. Bart Staal, Jacqueline Limpens, Harm Kuipers, Shelley E. Overbeek, Aeilko H. Zwinderman, Rob J. P. M. Scholten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Web of Science)

Abstract

Inhaled beta(2)-agonists are commonly used as bronchodilators in the treatment of asthma. Their use in athletes, however, is restricted by anti-doping regulations. Controversies remain as to whether healthy elite athletes who use bronchodilators may gain a competitive advantage. The aim of this systematic review and meta-analysis is to assess the effects of inhaled and systemic beta(2)-agonists on physical performance in healthy, nonasthmatic subjects. To this end, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to August 2009. Reference lists were searched for additional relevant studies. The search criteria were for randomized controlled trials examining the effect of inhaled or systemic beta(2)-agonists on physical performance in healthy, nonasthmatic subjects. Two authors independently performed the selection of studies, data extraction and risk of bias assessment. Parallel-group and crossover trials were analysed separately. Mean difference (MD) and 95% confidence intervals were calculated for continuous data and, where possible, data were pooled using a fixed effects model. Twenty-six studies involving 403 participants (age range 7-30 years) compared inhaled beta(2)-agonists with placebo. No significant effect could be detected for inhaled beta(2)-agonists on maximal oxygen consumption (VO2max) [MD -0.14 mL center dot kg(-1) center dot min(-1); 95% CI -1.07, 0.78; 16 studies], endurance time to exhaustion at 105-110% VO2max (MD -1.5 s; 95% CI -15.6, 12.6; four studies), 20-km time trial duration (MD -4.4 s; 95% CI -23.5, 14.7; two studies), peak power (MD -0.14 W center dot kg(-1); 95% CI -0.54, 0.27; four studies) and total work during a 30-second Wingate test (MD 0.80 J center dot kg(-1); 95% CI -2.44, 4.05; five studies). Thirteen studies involving 172 participants (age range 7-22 years) compared systemic beta(2)-agonists with placebo, with 12 studies involving oral and one study involving intravenous salbutamol. A significant effect was detected for systemic beta(2)-agonists on endurance time to exhaustion at 80-85%.VO2max (MD 402 s; 95% CI 34, 770; two studies), but not for VO2max (placebo 42.5 +/- 1.7 mL center dot kg(-1) center dot min(-1), salbutamol 42.1 +/- 2.9 mL center dot kg(-1) center dot min(-1), one study), endurance time to exhaustion at 70% VO2max (MD 400 s; 95% CI -408, 1208; one study) or power output at 90% VO2max (placebo 234.9 +/- 16 W, salbutamol 235.5 +/- 18.1 W, one study). A significant effect was shown for systemic beta(2)-agonists on peak power (MD 0.91 W center dot kg(-1); 95% CI 0.25, 1.57; four studies), but not on total work (MD 7.8 J center dot kg(-1); 95% CI -3.3, 18.9; four studies) during a 30-second Wingate test. There were no randomized controlled trials assessing the effects of systemic formoterol, salmeterol or terbutaline on physical performance. In conclusion, no significant effects were detected for inhaled beta(2)-agonists on endurance, strength or sprint performance in healthy athletes. There is some evidence indicating that systemic beta(2)-agonists may have a positive effect on physical performance in healthy subjects, but the evidence base is weak.
Original languageEnglish
Pages (from-to)39-57
JournalSports Medicine
Volume41
Issue number1
DOIs
Publication statusPublished - 2011

Cite this